Drug intelligence / Profile preview

hyperinsulinemic, euglycemic infusion

Development stage
Phase 1
Lead developer
University of Missouri
Modality
Small Molecules, Peptides
Administration
Intravenous
01

Overview

Hyperinsulinemic, euglycemic infusion, also known as the hyperinsulinemic-euglycemic clamp, is a gold-standard research intervention used to quantify insulin sensitivity and metabolic function. The procedure involves the continuous intravenous infusion of exogenous insulin to achieve a steady-state of hyperinsulinemia, which suppresses endogenous glucose production and stimulates peripheral glucose uptake. Simultaneously, a variable-rate glucose (dextrose) infusion is administered to maintain blood glucose levels within a normal range (euglycemia). The rate of glucose required to maintain this balance (the glucose infusion rate or GIR) serves as a direct measure of the body's sensitivity to insulin. In clinical research, such as studies conducted by the University of Missouri, this technique is employed to investigate physiological responses like blood flow and sympathetic nervous system activity in conditions such as obesity.

Other names
hyperinsulinemic-euglycemic clampinsulin-glucose clamphyperinsulinemic, euglycemic infusion
02

Targets

Insulin receptor/Insulin-like growth factor 1 receptor hybrid receptorINSR (Insulin receptor)IGF-1R (Insulin-like growth factor 1 receptor)

Beyond the preview

Go deeper on hyperinsulinemic, euglycemic infusion.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on hyperinsulinemic, euglycemic infusion.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call